Biologic and small-molecule medications in the management of pyoderma gangrenosum

Fatima McKenzie, Devin Cash, Angela Gupta, Laurel W. Cummings, Alex Ortega Loayza

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Pyoderma gangrenosum (PG) is an uncommon inflammatory skin disorder characterized by neutrophil dysfunction. There are currently no FDA-approved drugs for the treatment of this disease, and treatment has typically relied on traditional immunosuppressive medications such as prednisone or cyclosporine. The efficacy of biologics in the treatment of other pro-inflammatory conditions such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease is well-documented in the literature. Therefore, the use of biologic medications for the treatment of rarer inflammatory skin conditions, such as PG, is a compelling topic for investigation. Biologic and small-molecule therapies allow physicians to target specific pro-inflammatory mediators that underlie PG pathogenesis. This review provides an update on the use of biologic and small-molecule medications for the treatment of PG and summarizes the latest data on the clinical efficacy and pharmacology of these treatments.

Original languageEnglish (US)
JournalJournal of Dermatological Treatment
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Pyoderma Gangrenosum
Therapeutics
Skin
Clinical Pharmacology
Immunosuppressive Agents
Prednisone
Biological Products
Inflammatory Bowel Diseases
Psoriasis
Cyclosporine
Rheumatoid Arthritis
Neutrophils
Physicians
Pharmaceutical Preparations

Keywords

  • biologics
  • Pyoderma gangrenosum
  • small molecules

ASJC Scopus subject areas

  • Dermatology

Cite this

Biologic and small-molecule medications in the management of pyoderma gangrenosum. / McKenzie, Fatima; Cash, Devin; Gupta, Angela; Cummings, Laurel W.; Ortega Loayza, Alex.

In: Journal of Dermatological Treatment, 01.01.2018.

Research output: Contribution to journalArticle

@article{12714d2e96ce41149f3febaa55dc8e84,
title = "Biologic and small-molecule medications in the management of pyoderma gangrenosum",
abstract = "Pyoderma gangrenosum (PG) is an uncommon inflammatory skin disorder characterized by neutrophil dysfunction. There are currently no FDA-approved drugs for the treatment of this disease, and treatment has typically relied on traditional immunosuppressive medications such as prednisone or cyclosporine. The efficacy of biologics in the treatment of other pro-inflammatory conditions such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease is well-documented in the literature. Therefore, the use of biologic medications for the treatment of rarer inflammatory skin conditions, such as PG, is a compelling topic for investigation. Biologic and small-molecule therapies allow physicians to target specific pro-inflammatory mediators that underlie PG pathogenesis. This review provides an update on the use of biologic and small-molecule medications for the treatment of PG and summarizes the latest data on the clinical efficacy and pharmacology of these treatments.",
keywords = "biologics, Pyoderma gangrenosum, small molecules",
author = "Fatima McKenzie and Devin Cash and Angela Gupta and Cummings, {Laurel W.} and {Ortega Loayza}, Alex",
year = "2018",
month = "1",
day = "1",
doi = "10.1080/09546634.2018.1506083",
language = "English (US)",
journal = "Journal of Dermatological Treatment",
issn = "0954-6634",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Biologic and small-molecule medications in the management of pyoderma gangrenosum

AU - McKenzie, Fatima

AU - Cash, Devin

AU - Gupta, Angela

AU - Cummings, Laurel W.

AU - Ortega Loayza, Alex

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Pyoderma gangrenosum (PG) is an uncommon inflammatory skin disorder characterized by neutrophil dysfunction. There are currently no FDA-approved drugs for the treatment of this disease, and treatment has typically relied on traditional immunosuppressive medications such as prednisone or cyclosporine. The efficacy of biologics in the treatment of other pro-inflammatory conditions such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease is well-documented in the literature. Therefore, the use of biologic medications for the treatment of rarer inflammatory skin conditions, such as PG, is a compelling topic for investigation. Biologic and small-molecule therapies allow physicians to target specific pro-inflammatory mediators that underlie PG pathogenesis. This review provides an update on the use of biologic and small-molecule medications for the treatment of PG and summarizes the latest data on the clinical efficacy and pharmacology of these treatments.

AB - Pyoderma gangrenosum (PG) is an uncommon inflammatory skin disorder characterized by neutrophil dysfunction. There are currently no FDA-approved drugs for the treatment of this disease, and treatment has typically relied on traditional immunosuppressive medications such as prednisone or cyclosporine. The efficacy of biologics in the treatment of other pro-inflammatory conditions such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease is well-documented in the literature. Therefore, the use of biologic medications for the treatment of rarer inflammatory skin conditions, such as PG, is a compelling topic for investigation. Biologic and small-molecule therapies allow physicians to target specific pro-inflammatory mediators that underlie PG pathogenesis. This review provides an update on the use of biologic and small-molecule medications for the treatment of PG and summarizes the latest data on the clinical efficacy and pharmacology of these treatments.

KW - biologics

KW - Pyoderma gangrenosum

KW - small molecules

UR - http://www.scopus.com/inward/record.url?scp=85053331147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053331147&partnerID=8YFLogxK

U2 - 10.1080/09546634.2018.1506083

DO - 10.1080/09546634.2018.1506083

M3 - Article

JO - Journal of Dermatological Treatment

JF - Journal of Dermatological Treatment

SN - 0954-6634

ER -